Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Migraine Market

DelveInsight’s ‘Migraine – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the migraine, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Migraine market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted migraine symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Migraine symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Migraine Disease Understanding and Treatment Algorithm

Migraine Overview

Migraine is a neurological condition that can cause multiple symptoms. It is frequently characterized by intense, debilitating headaches. A migraine is a moderate or severe headache felt as a throbbing pain on one side of the head. Symptoms may include nausea, vomiting, difficulty speaking, numbness or tingling, and sensitivity to light and sound. Migraines often run in families and affect all ages.


The exact cause of migraines is unknown, but they are thought to be the result of abnormal brain activity temporarily affecting nerve signals, chemicals, and blood vessels in the brain. Many possible migraine triggers have been suggested, including hormonal, emotional, physical, dietary, environmental, and medicinal factors. These triggers vary among individuals, but a diary may help keep track of consistent triggers.


Spontaneous over activity and abnormal amplification in pain and other predominantly sensory pathways in the brainstem lead to migraine. Current opinion favors a primarily neural cause involving feedback loops through innervation of cranial arteries in the trigeminovascular system. The most common categories of migraine headaches are those without aura (previously known as common migraines) and those with aura (previously known as classic migraines).


Episodic migraine (EM) is characterized by those with migraine who have 0–14 headache days per month; it is classified into low-frequency EM (less than 10 headache days per month) and high-frequency EM (10–14 headache days per month), while chronic migraine (CM) is characterized by 15 or more headache days per month.


There is no specific test to diagnose migraines. For an accurate diagnosis to be made, one must identify a pattern of recurring headaches along with the associated symptoms. The diagnosis of migraine headaches is determined based on clinical history, reported symptoms, and by ruling out other causes. Imaging scans, such as a CT scan or MRI, can rule out other causes, including tumors, strokes, bleeding in the brain, infections, and other brain and nervous system (neurological) conditions.


There is currently no cure for migraines, although several treatments are available to help ease the symptoms. Most people find that sleeping or lying in a darkened room is the best thing to do when having a migraine attack. Over-the-counter medications are effective for some people with mild to moderate migraines. The main ingredients in pain-relieving medications are ibuprofen, aspirin, acetaminophen, naproxen, and caffeine.


Migraine Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the migraine market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Migraine market report gives a thorough understanding of MIGRAINE symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides MIGRAINE symptoms of treatment algorithms and treatment guidelines for Migraine symptoms in the US, Europe, and Japan.

Migraine Epidemiology

The epidemiology division’s Migraine symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine. The report includes the Incident scenario of MIGRAINE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Migraine Epidemiology

The epidemiology segment also provides the Migraine epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM Prevalent cases of migraine were 118,126 cases in 2020.

Migraine Drug Chapters

The drug chapter segment of the Migraine report encloses the detailed analysis of migraine marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Migraine clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


The primary revenue-generating components of the acute treatment market can be classified broadly into the following therapeutic classes, namely triptans, NSAIDs, analgesics/opioids and DHE (dihydroergotamine) or ergot alkaloids. Triptans continue to dominate the overall acute treatment landscape generating the highest amount of revenue. Some of the major drugs (generics/branded) belonging to this class are eletriptan, almotriptan, sumatriptan, rizatriptan, zolmitriptan, and few others.

Products detail in the report…


Migraine Emerging Drugs


Zavegepant (Biohaven Pharmaceuticals) is a third-generation, high affinity, selective, and structurally unique, small molecule CGRP receptor antagonist from Biohaven’s Nojection Migraine Platform and the only CGRP receptor antagonist in clinical development with both intranasal and oral formulations. The efficacy and safety profile of intranasal Zavegepant for the acute treatment of migraine, as compared to placebo, was shown in a randomized controlled Phase II/III dose-ranging trial with a total of over 1,000 patients who received Zavegepant.

Products detail in the report…

Migraine Market Outlook

The Migraine market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of the Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Migraine market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Migraine market in 7MM. The market size of migraine in the seven major markets was USD 5,592 million in 2020, and the market is estimated to increase for the study period (2018–2030).


The United States Market Outlook

This section provides a total of Migraine market size and market size by therapies in the United States.


The United States accounts for the largest MIGRAINE market size than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Migraine market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total migraine market size and market size by therapies in Japan are also mentioned.

Migraine Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Migraine market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Migraine Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Migraine key players involved in developing targeted therapeutics.


Major players are Zavegepant (Biohaven Pharmaceuticals), Atogepant (AbbVie), INP104 (Impel NeuroPharma), Zolmitriptan transdermal (Zosano Pharma), AXS-07 (Axsome Therapeutics), and others being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for migraine emerging therapies.

Reimbursement Scenario in Migraine

At the current price, it estimates that only a few patients who do not respond to one preventive treatment could be treated with erenumab without exceeding the cost burden that society is willing to bear. The substantial increase in triptan prescriptions in the last few years—without being convincingly explained by either rising migraine prevalence or rising Medicaid enrollment—suggests reduced access to these medications. Cost-containment policies may have inadvertently prevented Medicaid migraine from obtaining appropriate pharmacotherapy.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Migraine domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Migraine market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Migraine Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of migraine, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Migraine epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for migraine is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Migraine market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Migraine market

Report Highlights

  • In the coming years, the Migraine market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for MIGRAINE. The launch of emerging therapies will significantly impact the Migraine market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for migraine
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Migraine Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Migraine Pipeline Analysis
  • Migraine Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Migraine Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Migraine Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Migraine Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Key Questions

Market Insights:

  • What was the Migraine Market share (%) distribution in 2020, and how it would look in 2030?
  • What would be the Migraine total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Migraine market Size during the forecast period (2021–2030)?
  • At what CAGR, the Migraine market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Migraine market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Migraine market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of migraine?
  • What is the historical Migraine patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of migraine in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about migraine?
  • Out of all 7MM countries, which country would have the largest incident population of migraine during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of migraine?
  • What are the current treatment guidelines for treating migraine in the USA, Europe, and Japan?
  • What are the migraine marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of migraine?
  • How many therapies are developed by each company for the treatment of migraine?
  • How many emerging therapies are in the mid-stage and late stages of development to treat migraine?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Migraine therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for migraine and their status?
  • What are the key designations that have been granted for the emerging therapies for migraine?
  • What are the global historical and forecasted market of migraine?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Migrainemarket
  • To understand the future market competition in the Migraine market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Migraine in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Migraine market
  • To understand the future market competition in the Migraine market

1. Key Insights

2. Report Introduction

3. Migraine Market Overview at a Glance

3.1. Market Share (%) Distribution of Migraine in 2018

3.2. Market Share (%) Distribution of Migraine in 2030

4. Executive Summary of Migraine

5. Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.3. Cause

5.4. Risk Factors

5.5. Types of Migraine

5.7. Pathophysiology

5.8. Diagnosis

6. Treatment

6.1. American Headache Society Guidelines for Migraine

6.2. Guideline by Chronic Headache Clinical Practice Development Committee of Japan

6.3. Nice Guidelines for Migraine Management

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Migraine

7.3. Epidemiology of Migraine

7.4. The United States

7.4.1. Prevalence of Migraine in the United States

7.4.2. Prevalent Cases of Migraine by severity in the United States

7.4.3. Gender-specific Prevalence of Migraine in the United States

7.4.4. Diagnosed Cases of Episodic and Chronic Migraine in the United States

7.5. EU5

7.5.1. Germany

7.5.1.1. Prevalence of Migrainein Germany

7.5.1.2. Prevalent Cases of Migraine by severity in Germany

7.5.1.3. Gender-specific Prevalence of Migraine in Germany

7.5.1.4. Diagnosed Cases of Episodic and Chronic Migraine in Germany

7.5.2. France

7.5.2.1. Prevalence of Migraine in France

7.5.2.2. Prevalent Cases of Migraine by severity in France

7.5.2.3. Gender-specific Prevalence of Migraine in France

7.5.2.4. Diagnosed Cases of Episodic and Chronic Migraine in France

7.5.3. Italy

7.5.3.1. Prevalence of Migraine in Italy

7.5.3.2. Prevalent migraine by severity in Italy

7.5.3.3. Gender-specific Prevalence of Migraine in Italy

7.5.3.4. Diagnosed Cases of Episodic and Chronic Migraine in Italy

7.5.4. Spain

7.5.4.1. Prevalence of Migraine in Spain

7.5.4.2. Prevalent Cases of Migraine by severity in Spain

7.5.4.3. Gender-specific Prevalence of Migraine in Spain

7.5.4.4. Diagnosed Cases of Episodic and Chronic Migraine in Spain

7.5.5.   United Kingdom

7.5.5.1.  Prevalence of Migraine in the United Kingdom

7.5.5.2.  Prevalent Cases of Migraine by severity in the United Kingdom

7.5.2.4.  Gender-specific Prevalence of Migraine in the United Kingdom

7.5.2.5.  Diagnosed Cases of Episodic and Chronic Migraine in the United Kingdom

7.6. Japan

7.6.1. Prevalence of Migraine in Japan

7.6.2. Prevalent Cases of Migraine based on Severity in Japan

7.6.3. Gender-specific Prevalence of Migraine in Japan

7.6.4. Diagnosed Cases of Episodic and Chronic Migraine in Japan

8. Organizations contributing toward Migraine

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1.Vyepti (Eptinezumab): Lundbeck Seattle BioPharmaceutical

11.1.1. Drug Description

11.1.2. Regulatory Milestones

11.1.3. Safety and Efficacy

11.1.4. Product Profile

11.2.Emgality (Galcanezumab-gnlm): Eli Lilly and Company

11.2.1. Product Description

11.2.2. Mechanism of action

11.2.3. Regulatory Milestones

11.2.4. Safety and Efficacy of Emgality

11.2.5. Product Profile

11.3. Aimovig: Amgen/Novartis

11.3.1. Product Description

11.3.2. Mechanism of action

11.3.3. Regulatory Milestones

11.3.4. Other Developmental Activities

11.3.5. Clinical Development

11.3.6. Safety and Efficacy

11.3.7. Product Profile

11.4. Ajovy: Teva Pharmaceuticals

11.4.1. Product Description

11.4.2. Mechanism of action

11.4.3. Regulatory Milestones

11.4.4. Other developmental Activities

11.4.5. Clinical Development

11.4.6. Safety and Efficacy

11.4.7. Product Profile

11.5.Ubrelvy: Allergan

11.5.1. Product Description

11.5.2. Regulatory Milestones

11.5.3. Safety and Efficacy

11.5.4. Product Profile

11.6. Rimegepant (Nurtec ODT): Biohaven Pharmaceuticals

11.6.1. Product Description

11.6.2. Regulatory Milestones

11.6.3. Clinical Development

11.6.4. Safety and Efficacy

11.6.5. Product Profile

11.7. Tosymra nasal spray: Dr. Reddy’s Labs

11.7.1. Product Description

11.7.2. Mechanism of action

11.7.3. Regulatory Milestones

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. Reyvow: Eli Lilly and Company

11.8.1. Product Description

11.8.2. Mechanism of action

11.8.3. Regulatory Milestones

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. Botox: Allergan

11.9.1. Product Description

11.9.2. Regulatory Milestones

11.9.3. Safety and Efficacy

11.9.4. Product Profile

12. Emerging Therapies

12.1. Zavegepant: Biohaven Pharmaceuticals

12.1.1. Drug Description

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Safety and Efficacy

12.1.5. Product Profile

12.2. Atogepant: AbbVie

12.2.1. Drug Description

12.2.2. Clinical Development

12.2.3. Clinical Trials Information

12.2.4. Safety and Efficacy

12.2.5. Product Profile

12.3. INP104: Impel NeuroPharma

12.3.1. Drug Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Safety and Efficacy

12.3.6. Product Profile

12.4. Zolmitriptan transdermal: Zosano Pharma

12.4.1. Drug Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Safety and Efficacy

12.4.6. Product Profile

12.5. AXS-07: Axsome Therapeutics

12.5.1. Drug Description

12.5.2. Clinical Development

12.5.3. Clinical Trials Information

12.5.4. Safety and Efficacy

12.5.5. Product Profile

13. Migraine: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Migraine in 7MM

14. Market Outlook

14.1. Assumption and Rationale

14.2. United States Market Size

14.2.1. Total Market Size of Migraine in the United States

14.2.2. Market Size of Episodic Migraine for preventive Therapies in the United States

14.2.3. Market Size of Episodic Migraine for Acute Therapies in the United States

14.2.4. Market Size of Chronic Migraine for preventive Therapies in the United States

14.2.5. Market Size of Chronic Migraine for Acute therapies in the United States

14.3. EU-5 Market Size

14.3.1. Germany

14.3.1.1. Total Market size of Migraine in Germany

14.3.1.2. Market Size of Episodic Migraine for preventive Therapies in Germany

14.3.1.3. Market Size of Episodic Migraine for Acute Therapies in Germany

14.3.1.4. Market Size of Chronic Migraine for preventive Therapies in Germany

14.3.1.5. Market Size of Chronic Migraine for Acute Therapies in Germany

14.3.2. France

14.3.2.1. Total Market size of Migraine in France

14.3.2.2.  Market Size of Episodic Migraine for preventive Therapies in France

14.3.2.3. Market Size of Episodic Migraine for Acute Therapies in France

14.3.2.4. Market Size of Chronic Migraine for preventive Therapies in France

14.3.2.5. Market Size of Chronic Migraine for Acute Therapies in France

14.3.3. Italy

14.3.3.1. Total Market size of Migraine in Italy

14.3.3.2. Market Size of Episodic Migraine for preventive Therapies in Italy

14.3.3.3. Market Size of Episodic Migraine for Acute Therapies in Italy

14.3.3.4. Market Size of Chronic Migraine for preventive Therapies in Italy

14.3.3.5. Market Size of Chronic Migraine for Acute Therapies in Italy

14.3.4. Spain

14.3.4.1. Total Market size of Migraine in Spain

14.3.4.2. Market Size of Episodic Migraine for preventive Therapies in Spain

14.3.4.3. Market Size of Episodic Migraine for Acute Therapies in Spain

14.3.4.4. Market Size of Chronic Migraine for preventive Therapies in Spain

14.3.4.5. Market Size of Chronic Migraine for Acute Therapies in Spain

14.3.5. United Kingdom

14.3.5.1. Total Market size of migraine in the United Kingdom

14.3.5.2. Market Size of Episodic Migraine for preventive Therapies in the UK

14.3.5.3. Market Size of Episodic Migraine for Acute Therapies in the UK

14.3.5.4. Market Size of Chronic Migraine for preventive Therapies in the UK

14.3.5.5. Market Size of Chronic Migraine for Acute Therapies in the UK

14.4.Japan

14.4.1. Total Market size of Migraine in Japan

14.4.2. Market Size of Episodic Migraine for preventive Therapies in Japan

14.4.3. Market Size of Episodic Migraine for Acute Therapies in Japan

14.4.4. Market Size of Chronic Migraine for preventive Therapies in Japan

14.4.5. Market Size of Chronic Migraine for Acute Therapies in Japan

15. Market Access

16. Market Drivers

17. Market Barriers

18. Unmet Needs

19. SWOT Analysis

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of MIGRAINE, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Patient Characteristics of EM vs. CM

Table 3: ICHD-3 (Beta) Criteria for Migraine With Aura

Table 4: ICHD-3 (Beta) Criteria for Migraine Without Aura

Table 5: ICHD-3 (Beta) Diagnostic Criteria for CM

Table 6: Differential Diagnosis of Primary Chronic Headache of Long Duration

Table 7: Total Prevalent Patient Population of Migraine in 7MM (2018–2030)

Table 8: Prevalence of Migraine in the United States (2018–2030)

Table 9: Prevalent Cases of Migraine based on clinical Manifestation in the United States (2018–2030)

Table 10: Gender-specific Prevalence of Migraine in the United States (2018–2030)

Table 11: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2018–2030)

Table 12: Prevalence of Migraine in Germany (2018–2030)

Table 13: Prevalent Cases of Migraine by severity in Germany (2018–2030)

Table 14: Gender-specific Prevalence of Migraine in Germany (2018–2030)

Table 15: Diagnosed Cases of Episodic and Chronic Migraine in Germany (2018–2030)

Table 16: Prevalence of Migraine in France (2018–2030)

Table 17: Prevalent Cases of Migraine by severity in France (2018–2030)

Table 18: Gender-specific Prevalence of Migraine in France (2018–2030)

Table 19: Diagnosed Cases of Episodic and Chronic Migraine in France (2018–2030)

Table 20: Prevalence of Migraine in Italy (2018–2030)

Table 21: Prevalent Cases of Migraine by severity in Italy (2018–2030)

Table 22: Gender-specific Prevalence of Migraine in Italy (2018–2030)

Table 23: Diagnosed Cases of Episodic and Chronic Migraine in Italy (2018–2030)

Table 24: Prevalence of Migraine in Spain (2018–2030)

Table 25: Prevalent Cases of Migraine by severity in Spain (2018–2030)

Table 26: Gender-specific Prevalence of Migraine in Spain (2018–2030)

Table 27: Diagnosed Cases of Episodic and Chronic Migraine in Spain (2018–2030)

Table 28: Prevalence of Migraine in United Kingdom (2018–2030)

Table 29: Prevalent Cases of Migraine by severity in United Kingdom (2018–2030)

Table 30: Gender-specific Prevalence of Migraine in the United Kingdom (2018–2030)

Table 31: Diagnosed Cases of Episodic and Chronic Migraine in the United Kingdom (2018–2030)

Table 32: Prevalence of Migraine in Japan (2018–2030)

Table 33: Prevalent Cases of Migraine by severity in Japan (2018–2030)

Table 34: Gender-specific Prevalence of Migraine in Japan (2018–2030)

Table 35: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2018–2030)

List of Figures

Figure 1: Multiple factors contribute to migraine chronification

Figure 2: Algorithmic approach to diagnosing migraine

Figure 3: Multiple factors contribute to migraine chronification

Figure 4: Total Prevalent Population of Migraine in 7MM (2018–2030)

Figure 5: Prevalence of Migraine in the United States (2018–2030)

Figure 6: Prevalent Cases of Migraine by severity in the United States (2018–2030)

Figure 7: Gender-specific Prevalence of Migraine in the United States (2018–2030)

Figure 8: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2018–2030)

Figure 9: Prevalence of Migraine in Germany (2018–2030)

Figure 10: Prevalent Cases of Migraine by severity in Germany (2018–2030)

Figure 11: Gender-specific Prevalence of Migraine in Germany (2018–2030)

Figure 12: Diagnosed Cases of Episodic and Chronic Migraine in Germany (2018–2030)

Figure 13: Prevalence of Migraine in France (2018–2030)

Figure 14: Prevalent Cases of Migraine by severity in France (2018–2030)

Figure 15: Gender-specific Prevalence of Migraine in France (2018–2030)

Figure 16: Diagnosed Cases of Episodic and Chronic Migraine in France (2018–2030)

Figure 17: Prevalence of Migraine in Italy (2018–2030)

Figure 18: Prevalent Cases of Migraine by in Italy (2018–2030)

Figure 19: Gender-specific Prevalence of Migraine in Italy (2018–2030)

Figure 20: Diagnosed Cases of Episodic and Chronic Migraine in Italy (2018–2030)

Figure 21: Prevalence of Migraine in Spain (2018–2030)

Figure 22: Prevalent Cases of Migraine by severity in Spain (2018–2030)

Figure 23: Gender-specific Prevalence of Migraine in Spain (2018–2030)

Figure 24: Diagnosed Cases of Episodic and Chronic Migraine in Spain (2018–2030)

Figure 25: Prevalence of Migraine in United Kingdom (2018–2030)

Figure 26: Prevalent Cases of Migraine by severityin United Kingdom (2018–2030)

Figure 27: Gender-specific Prevalence of Migraine in the United Kingdom (2018–2030)

Figure 28: Diagnosed Cases of Episodic and Chronic Migraine in the United Kingdom (2018–2030)

Figure 29: Prevalence of Migraine in Japan (2018–2030)

Figure 30: Prevalent Cases of Migraine by severity in Japan (2018–2030)

Figure 31: Gender-specific Prevalence of Migraine in Japan (2018–2030)

Figure 32: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2018–2030)

Figure 33: 7 Major Market Size of Migraine in USD Million (2018–2030)

Figure 34: Total Market Size of Episodic and Chronic Migraine in the United States, USD Million (2018–2030)

Figure 35: The United States Market Size of Migraine by Therapies in USD Million

Figure 36: The United States Market Size of Migraine by Therapies in USD Million

Figure 37: The United States Market Size of Migraine by Therapies in USD Million

Figure 38: The United States Market Size of Migraine by Therapies in USD Million

Figure 39: Total Market Size of Episodic and Chronic Migraine in the Germany, USD Million (2018–2030)

Figure 40: The Germany Market Size of Episodic Migraine for preventive Therapies in USD Million

Figure 41: The Germany Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 42: The Germany Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 43: The Germany Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 44: Market Size of Migraine in the France, USD Million (2018–2030)

Figure 45: France Market Size of Episodic Migraine for preventive Therapies in USD Million

Figure 46: France Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 47: France Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 48: France Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 49: Market Size of Migraine in the Italy, USD Million (2018–2030)

Figure 50: Italy Market Size of Episodic Migraine for preventive Therapies in USD Million

Figure 51: Italy Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 52: Italy Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 53: Italy Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 54: Market Size of Migraine in the Spain, USD Million (2018–2030)

Figure 55: Spain Market Size of Episodic Migraine for preventive Therapies in USD Million

Figure 56: Spain Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 57: Spain Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 58: Spain Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 59: Market Size of Migraine in the United Kingdom, USD Million (2018–2030)

Figure 60: United Kingdom Market Size of Episodic Migraine for preventive Therapies in USD Million

Figure 61: United Kingdom Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 62: United Kingdom Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 63: United Kingdom Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 64: Market Size of Migraine in the Japan, USD Million (2018–2030)

Figure 65: Japan Market Size of Migraine by Therapies in USD Million

Figure 66: Japan Market Size of Migraine by Therapies in USD Million

Figure 67: Japan Market Size of Migraine by Therapies in USD Million

Figure 68: Japan Market Size of Migraine by Therapies in USD Million (2018–2030)

Lundbeck Seattle BioPharmaceutical

Eli Lilly and Company

Amgen/Novartis

Teva Pharmaceuticals

Allergan

Biohaven Pharmaceuticals

Dr. Reddy’s Labs

Eli Lilly and Company

Allergan

Biohaven Pharmaceuticals

AbbVie

Impel NeuroPharma

Zosano Pharma

Axsome Therapeutics

Forward to Friend

Need A Quote